Source disclosure: February 16, 2026
Chordia Therapeutics Inc. [190A.T]
TOKYO, Feb 16 (Pulse News Wire) – Chordia Therapeutics Inc. (190A.T) announced today that it has concluded a termination agreement with Otsuka Pharmaceutical Co.
Ltd. regarding the license contract for its drug development pipeline CTX-177 (ONO7,018). The agreement pertains to the rights for development, manufacturing, and commercialization previously granted to Otsuka. Under the terms of the agreement, data obtained by Otsuka during the licensing period will be transferred back to Chordia Therapeutics without charge, alleviating any financial burden on the company. Additionally, Chordia Therapeutics and Otsuka have agreed that Chordia will become the sole applicant for patents related to combined therapies involving CTX-177 and other anticancer drugs.
Chordia will bear the costs associated with future procedures and reviews for these patents. Otsuka will handle the closure of ongoing clinical trials independently. The impact on Chordia's fiscal year ending August 2026 is expected to be minor. Chordia plans to leverage the acquired clinical trial data to explore strategic options for restarting CTX-177’s development. The pipeline remains scientifically promising, and efforts to enhance the company's value through re-commercialization initiatives will continue.
AI-translated content. 🟢 Confidence: High See terms • Original filing